Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $48.33 USD
Change Today -2.11 / -4.18%
Volume 755.2K
KYTH On Other Exchanges
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

kythera biopharmaceuticals i (KYTH) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/9/15 - $56.00
52 Week Low
05/9/14 - $29.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

kythera biopharmaceuticals i (KYTH) Related Bloomberg News

View More Bloomberg News

kythera biopharmaceuticals i (KYTH) Related Businessweek News

No Related Businessweek News Found

kythera biopharmaceuticals i (KYTH) Details

KYTHERA Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription products for the aesthetic medicine market in the United States and internationally. Its product candidate ATX-101, is an injectable drug in late-stage clinical development for the the reduction of submental fat. The company also maintains research interest in hair and fat biology, pigmentation modulation, and facial contouring. It has a collaboration arrangement with Bayer Consumer Care AG and a related collaboration agreement with Bayer Consumer Care AG’s affiliate, Intendis GmbH to develop and commercialize ATX-101 outside the United States and Canada. The company was formerly known as AESTHERx, Inc. and changed its name to KYTHERA Biopharmaceuticals, Inc. in July, 2006. KYTHERA Biopharmaceuticals, Inc. was founded in 2004 and is headquartered in Westlake Village, California.

106 Employees
Last Reported Date: 03/2/15
Founded in 2004

kythera biopharmaceuticals i (KYTH) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $495.1K
Chief Financial Officer
Total Annual Compensation: $336.0K
Chief Medical Officer
Total Annual Compensation: $446.6K
Compensation as of Fiscal Year 2014.

kythera biopharmaceuticals i (KYTH) Key Developments

Kythera Biopharmaceuticals, Inc. Provides Financial Guidance for 2015

Kythera Biopharmaceuticals, Inc. provided financial guidance for 2015. The company expects operating expenses, which excludes COGS and interest expense, for 2015 to be in a range of approximately $115 million to $125 million. Looking beyond operating expenses, the company estimate interest expense will be approximately $4 million in 2015.

Kythera Biopharmaceuticals, Inc., 2015 Guidance/Update Call, Mar 26, 2015

Kythera Biopharmaceuticals, Inc., 2015 Guidance/Update Call, Mar 26, 2015

KYTHERA Biopharmaceuticals Announces FDA Advisory Committee Recommends to Approve ATX-101 (Deoxycholic Acid) Injection to Improve the Appearance of Moderate to Severe Submental Fullness

KYTHERA Biopharmaceuticals, Inc. announced that the U.S. Food and Drug Administration's (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has voted to support the approval of ATX-101 (deoxycholic acid) injection for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults, which is often referred to as a double chin. The committee's recommendation, although not binding, will be considered by the FDA as it continues its review of ATX-101. If approved by the FDA, KYTHERA anticipates launching ATX-101 in the second half of 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KYTH:US $48.33 USD -2.11

KYTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KYTH.
View Industry Companies

Industry Analysis


Industry Average

Valuation KYTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 19.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYTHERA BIOPHARMACEUTICALS I, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at